Asthma Exacerbation Management

Primary Treatment Components

The American Thoracic Society recommends administering oxygen through nasal cannulae or mask to maintain oxygen saturation (SaO₂) >90% (>95% in pregnant patients or those with heart disease) 1
The American College of Allergy, Asthma, and Immunology suggests monitoring oxygen saturation until a clear response to bronchodilator therapy has occurred 1
Administer albuterol via nebulizer or metered-dose inhaler (MDI) with spacer, with dosing options including 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed, as recommended by the National Asthma Education and Prevention Program 2
The American Academy of Allergy, Asthma, and Immunology recommends administering systemic corticosteroids early, with oral prednisone 40-60 mg in single or divided doses, as the strength of evidence for this fact is high 2

Adjunctive Therapies

The American Thoracic Society suggests adding ipratropium bromide to beta-agonist therapy for severe exacerbations, with dosing options including 0.5 mg every 20 minutes for 3 doses, then as needed 1
The American College of Chest Physicians recommends considering magnesium sulfate for patients with severe refractory asthma, with a standard adult dose of 2 g IV administered over 20 minutes, as the strength of evidence for this fact is moderate 3

Treatment Strategy

The National Asthma Education and Prevention Program recommends an initial assessment within the first 15-30 minutes, including administering oxygen, giving the first dose of inhaled albuterol, and administering systemic corticosteroids, with a strength of evidence rating of A 4
The American Thoracic Society suggests reassessing the patient 15-30 minutes after starting treatment, measuring peak expiratory flow (PEF) or FEV₁, and assessing symptoms and vital signs, as the strength of evidence for this fact is high 4

Monitoring Parameters

The American College of Allergy, Asthma, and Immunology recommends measuring PEF or FEV₁ before and after treatments, with a strength of evidence rating of A 4
The American Academy of Allergy, Asthma, and Immunology suggests monitoring oxygen saturation continuously, as the strength of evidence for this fact is high 1

Asthma Exacerbation Management

Initial Assessment and Treatment

The severity of an asthma exacerbation can be determined based on symptoms, signs, and lung function (PEF or FEV1), with mild exacerbations characterized by dyspnea only with activity and PEF ≥70% of predicted or personal best, moderate exacerbations characterized by dyspnea that interferes with usual activity and PEF 40-69% of predicted, and severe exacerbations characterized by dyspnea at rest and PEF <40% of predicted 5
The American Academy of Allergy, Asthma, and Immunology recommends administering albuterol via nebulizer or metered-dose inhaler (MDI) with spacer, with MDI dosing of 4-12 puffs every 20 minutes for up to 3 hours as needed 6

Systemic Corticosteroids and Adjunctive Therapies

The American College of Chest Physicians recommends administering oral prednisone 40-60 mg in single or divided doses for adults with moderate to severe exacerbations, and 1-2 mg/kg/day (maximum 60 mg/day) for children, with oral administration being as effective as intravenous administration and less invasive 6, 7
The combination of a beta-agonist and ipratropium has been shown to reduce hospitalizations in patients with severe airflow obstruction, with ipratropium dosing of 0.5 mg every 20 minutes for 3 doses, then as needed 6, 7

Monitoring and Treatment Duration

Response to treatment is a better predictor of hospitalization need than initial severity, and early administration of corticosteroids may reduce hospitalization rates 6
The American Thoracic Society recommends a treatment duration of 5-10 days for outpatient "burst" therapy with 40-60 mg prednisone in single or divided doses for adults, and 1-2 mg/kg/day (maximum 60 mg/day) for 3-10 days for children 7

Medications for Asthma Exacerbation That Won't Cause Hypokalemia

Primary Treatment Options

Inhaled ipratropium bromide is the most effective medication for asthma exacerbations that doesn't cause hypokalemia, and should be added to standard therapy for all moderate to severe exacerbations, as recommended by the American Academy of Allergy, Asthma, and Immunology 8, 9
The American College of Chest Physicians recommends inhaled ipratropium bromide dosing of 0.5 mg via nebulizer or 8 puffs via MDI every 20 minutes for 3 doses, then as needed for adults 9
The American Academy of Pediatrics recommends inhaled ipratropium bromide dosing of 0.25-0.5 mg via nebulizer or 4-8 puffs via MDI every 20 minutes for 3 doses for children 9
Systemic corticosteroids, such as prednisone, do not cause significant hypokalemia and are essential for all moderate to severe exacerbations, according to the National Asthma Education and Prevention Program 8, 10
The American College of Allergy, Asthma, and Immunology recommends adult dosing of prednisone 40-80 mg/day in 1-2 divided doses until peak expiratory flow (PEF) reaches 70% of predicted or personal best 11
The American Academy of Pediatrics recommends child dosing of 1-2 mg/kg in 2 divided doses (maximum 60 mg/day) for prednisone 11

Adjunctive Therapies Without Hypokalemia Risk

Inhaled corticosteroids can be started at any point during an asthma exacerbation and do not cause hypokalemia, as stated by the Global Initiative for Asthma 11
The American College of Allergy, Asthma, and Immunology recommends considering initiating inhaled corticosteroids at discharge in patients not already receiving them 10

Management Algorithm

For all moderate to severe exacerbations, the National Asthma Education and Prevention Program recommends starting with systemic corticosteroids (oral prednisone preferred) and adding ipratropium bromide to beta-agonist therapy 8, 9, 10
At discharge, the Global Initiative for Asthma recommends continuing oral corticosteroids for 3-10 days and considering initiating or increasing inhaled corticosteroids 10

Asthma Acute Exacerbation Management

Initial Assessment and Recognition

The British Thoracic Society recommends recognizing features of severe asthma exacerbation, including inability to complete sentences in one breath, respiratory rate >25 breaths/min, PEF <50% of predicted/best, and heart rate >110 beats/min 12, 13
Life-threatening features of asthma exacerbation include PEF <33% of predicted/best, silent chest, cyanosis, feeble respiratory effort, bradycardia, hypotension, exhaustion, confusion, or coma 12, 14
Arterial blood gas markers of severe, life-threatening asthma attack include normal/high PaCO₂ in a breathless asthmatic, severe hypoxia (PaO₂ <8 kPa), and low pH 13, 15

Immediate Management Algorithm

The British Thoracic Society recommends administering high-dose inhaled beta-agonist, such as salbutamol 5 mg or terbutaline 10 mg, via nebulizer or multiple actuations of MDI with spacer 12, 13
For children, the British Medical Journal recommends salbutamol 5 mg or terbutaline 10 mg via oxygen-driven nebulizer, with half doses in very young children 16, 17
The British Thoracic Society recommends immediately administering prednisolone 30-60 mg orally or IV hydrocortisone 200 mg, with a strength of evidence grade of high 12

Monitoring and Reassessment

The British Medical Journal recommends monitoring oxygen saturation continuously and measuring PEF or FEV₁ and assessing symptoms and vital signs after starting treatment 16, 17
If the patient is improving, the British Medical Journal recommends continuing oxygen, prednisolone 30-60 mg daily or IV hydrocortisone 200 mg every 6 hours, and nebulized beta-agonist every 4-6 hours 16, 17

Common Pitfalls and Caveats

The British Thoracic Society notes that the severity of an asthma attack is often underestimated by patients, relatives, and doctors due to failure to make objective measurements 12, 13
The British Medical Journal recommends not administering sedatives of any kind to patients with acute asthma exacerbation 16
For children, the British Medical Journal notes that blood gas estimations are rarely helpful in deciding initial management, with a strength of evidence grade of moderate 16, 17

Acute Asthma Exacerbation Management

Bronchodilator Therapy

The American Academy of Allergy, Asthma, and Immunology recommends administering albuterol (short-acting β2-agonist) as first-line treatment via nebulizer or metered-dose inhaler (MDI) with spacer, with nebulizer dosing: 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed, and MDI dosing: 4-8 puffs every 20 minutes for up to 3 doses, then as needed 18
Adding ipratropium bromide to albuterol for severe exacerbations increases bronchodilation, with dosing: 0.5 mg via nebulizer or 8 puffs via MDI every 20 minutes for 3 doses, then as needed, and reduces hospitalizations, particularly in patients with severe airflow obstruction 18

Monitoring and Reassessment

All patients should undergo repeat assessment after the initial dose of inhaled bronchodilator treatment, with response to treatment being a better predictor of hospitalization need than initial severity 18

Adjunctive Therapies

Consider intravenous magnesium sulfate (2g IV over 20 minutes) for patients with severe refractory asthma or life-threatening exacerbations, and antibiotics are not generally recommended unless there is strong evidence of bacterial infection (e.g., pneumonia or sinusitis) 18
Aggressive hydration is not recommended for older children and adults but might be appropriate for some infants and young children 18

Recognition of Impending Respiratory Failure

Monitor for signs of impending respiratory failure: inability to speak, altered mental status, intercostal retraction, worsening fatigue, and PaCO2 ≥42 mm Hg, and do not delay intubation once it is deemed necessary 18
Consider other treatments such as intravenous magnesium, heliox, and other therapies before resorting to intubation 18

Management of Asthma Exacerbation

Initial Assessment and Treatment

The European Respiratory Society recommends antibiotics are not generally recommended unless there is strong evidence of bacterial infection, such as pneumonia or sinusitis 19

Treatment Based on Severity

For mild exacerbation, the European Respiratory Society recommends SABA via MDI with spacer (2-10 puffs) and considers oral corticosteroids 19, 20
For moderate exacerbation, the European Respiratory Society recommends SABA via nebulizer or MDI with spacer, oral corticosteroids, oxygen supplementation to maintain saturation >92-95%, and considers adding ipratropium bromide 19, 20
For severe exacerbation, the European Respiratory Society recommends SABA via nebulizer, systemic corticosteroids, oxygen supplementation, and considers IV magnesium sulfate 19, 20

Medication Dosages

The European Respiratory Society recommends methylprednisolone: 1-2 mg/kg IV 20
The European Respiratory Society recommends hydrocortisone: 4-7 mg/kg IV every 8 hours 20
The European Respiratory Society recommends dexamethasone: dosage for 3-5 days 20
The European Respiratory Society recommends albuterol nebulizer: 2.5-5.0 mg up to three times every 20 min over the first hour 20

Management of Asthma Exacerbation Unresponsive to Initial Therapy

Initial Assessment and Management

The British Thoracic Society recommends continuing high-dose inhaled beta-agonists, such as salbutamol 5 mg or terbutaline 10 mg via nebulizer with oxygen, every 20 minutes for 3 doses, to manage asthma exacerbation unresponsive to initial therapy 21

Escalation of Treatment

The American Thoracic Society suggests administering systemic corticosteroids immediately, such as prednisolone 30-60 mg orally or intravenous hydrocortisone 200 mg, to reduce inflammation in patients with severe asthma exacerbations 21
The British Thoracic Society recommends giving nebulized beta-agonists more frequently, up to every 15 minutes, if there is no improvement after 15-30 minutes, to manage severe asthma exacerbations 21

Diagnostic Imaging

A chest X-ray is indicated to exclude complications such as pneumothorax, consolidation, or pulmonary edema in patients with asthma exacerbation unresponsive to initial therapy, according to the British Thoracic Society 21

Monitoring and Reassessment

The British Thoracic Society recommends measuring and recording peak expiratory flow (PEF) 15-30 minutes after starting treatment and thereafter according to response, to assess the effectiveness of treatment in patients with asthma exacerbation 21

Criteria for Hospital Admission

The American College of Chest Physicians recommends hospital admission for patients with life-threatening features or features of a severe attack that persist after initial treatment, such as PEF <33% of predicted or best value 21

Discharge Planning (After Stabilization)

The Global Initiative for Asthma recommends that patients should not be discharged until symptoms have stabilized or returned to normal function, with a PEF above 75% of predicted value or best level, and diurnal variability below 25% 21
The British Thoracic Society suggests ensuring patients have appropriate maintenance therapy and a written self-management plan before discharge, and arranging follow-up with primary care within 1 week and specialist clinic within 4 weeks 22

Treatment of Mild Asthma Exacerbation with Short-acting Beta-agonists

Initial Treatment and Medication

Regular use of SABAs, such as albuterol, four or more times daily can reduce their duration of action, according to the American Academy of Family Physicians 23

Medication Usage and Effectiveness

The American Academy of Family Physicians notes that regular use of SABAs can lead to reduced effectiveness, highlighting the need for careful management and monitoring of medication use 23

Management of Moderate Asthma Exacerbation

Initial Assessment and Treatment

A moderate asthma exacerbation is characterized by deterioration in symptoms, deterioration in lung function, and increased rescue bronchodilator use lasting for 2 days or more, according to the American Thoracic Society 24, 25

Systemic Corticosteroids

Tapering is not necessary for courses of less than 10 days, as stated by the American Academy of Family Physicians 26

Initial Management of Acute Asthma Exacerbation

Criteria for Hospital Admission

A lower threshold for admission is appropriate in patients seen in the afternoon/evening, with recent onset of nocturnal symptoms, previous severe attacks, poor assessment of severity, or concerning social circumstances, as recommended by the British Thoracic Society 27

Acute Asthma Exacerbation Management

Initial Assessment and Treatment

The American Academy of Allergy, Asthma, and Immunology recommends classifying asthma exacerbation severity, with life-threatening features including PEF <33% predicted, silent chest, cyanosis, altered mental status, PaCO₂ ≥42 mmHg, and inability to speak 28
For severe exacerbations, the American College of Chest Physicians suggests considering continuous nebulization of short-acting beta-agonists like albuterol 28

Pharmacological Interventions

The American Academy of Allergy, Asthma, and Immunology recommends administering systemic corticosteroids early, with adults receiving 40-60 mg of prednisone PO and children receiving 1-2 mg/kg/day PO (maximum 60 mg/day) 28
Ipratropium bromide should be added to albuterol for all moderate-to-severe exacerbations, with evidence showing reduced hospitalizations, particularly in severe airflow obstruction 28

Reassessment and Escalation

The American Thoracic Society suggests reassessing patients after initial treatment (15-30 minutes) and after 3 doses of bronchodilator (60-90 minutes), including subjective response, physical findings, and objective measurements 28
For life-threatening exacerbations or severe exacerbations remaining after 1 hour of intensive treatment, intravenous magnesium sulfate may be indicated, with a dose of 2 g IV over 20 minutes 28

Avoiding Common Pitfalls

The American Academy of Allergy, Asthma, and Immunology advises against administering sedatives, aggressive hydration in older children and adults, and routine prescription of antibiotics unless strong evidence of bacterial infection exists 28
Methylxanthines, chest physiotherapy, and mucolytics should also be avoided 28

Management of Acute Exacerbation of Bronchial Asthma

Pharmacological Interventions

The American Thoracic Society recommends avoiding methylxanthines (theophylline) due to increased side effect profiles without superior efficacy 29

Adjunctive Therapies

No other cited facts were found in the article that met the specified criteria.

Asthma Exacerbation Treatment Guidelines

Primary Bronchodilator Therapy

The American Academy of Allergy, Asthma, and Immunology recommends administering albuterol as first-line treatment with dosing options, including nebulizer and MDI with spacer, which are equally effective when properly administered 30

Systemic Corticosteroids - Critical Early Intervention

The American Academy of Allergy, Asthma, and Immunology recommends administering systemic corticosteroids early in all moderate to severe exacerbations, with adult dosing of prednisone 40-60 mg orally and pediatric dosing of 1-2 mg/kg/day, and oral administration is as effective as intravenous 30
The American Academy of Allergy, Asthma, and Immunology recommends a duration of 5-10 days for outpatient "burst" therapy, with no tapering necessary for courses less than 10 days 30

Adjunctive Ipratropium Bromide

The American Academy of Allergy, Asthma, and Immunology recommends adding ipratropium bromide to albuterol for all moderate to severe exacerbations, with dosing of 0.5 mg via nebulizer or 8 puffs via MDI every 20 minutes for 3 doses, then as needed 30

Severe or Refractory Exacerbations

The American Academy of Allergy, Asthma, and Immunology recommends considering intravenous magnesium sulfate for severe exacerbations not responding to initial therapy, with dosing of 2 g over 20 minutes for adults or 25-75 mg/kg up to 2 g maximum for children 30

Common Pitfalls to Avoid

The American Academy of Allergy, Asthma, and Immunology recommends not delaying intubation once it is deemed necessary, and it should be performed semi-electively before respiratory arrest occurs 30

Discharge Criteria and Follow-up

The American Academy of Allergy, Asthma, and Immunology recommends ensuring PEF reaches 70% of predicted or personal best before discharge 30

Asthma Exacerbation Management

Initial Treatment and Assessment

The American Academy of Allergy, Asthma, and Immunology recommends observing patients for 30-60 minutes after the last bronchodilator dose to ensure stability before discharge, with a good response defined as PEF ≥70% predicted and minimal symptoms 31
Patients with a PEF <50% predicted after 1-2 hours of treatment should be considered for hospital admission, as this indicates a poor response to initial treatment 31
The National Asthma Education and Prevention Program suggests that a PEF ≥70% predicted or personal best, with symptoms minimal or absent, and oxygen saturation stable on room air, are criteria for discharge 31

Discharge Planning and Medications

The American College of Allergy, Asthma, and Immunology recommends continuing oral corticosteroids for 5-10 days after discharge, with no taper needed for courses <10 days, and initiating or continuing inhaled corticosteroids 31
Patients at high risk of non-adherence may benefit from an IM depot corticosteroid injection at discharge, according to the American Academy of Allergy, Asthma, and Immunology 31
Providing a written asthma action plan and reviewing inhaler technique are crucial components of patient education and follow-up, as recommended by the National Asthma Education and Prevention Program 31

Management of Asthma Exacerbation

Initial Assessment and Treatment

The American Thoracic Society recommends assessing severity immediately using symptoms, vital signs, and peak expiratory flow (PEF) or FEV₁, and administering oxygen to maintain SaO₂ >90% (>95% in pregnant patients or those with heart disease) 32, 33

Discharge Criteria and Planning

The National Asthma Education and Prevention Program recommends that patients may be discharged when PEF ≥70% of predicted or personal best, symptoms are minimal or absent, oxygen saturation is stable on room air, and the patient is stable for 30-60 minutes after the last bronchodilator dose, and ensuring continuation of oral corticosteroids for 5-10 days (no taper needed) and initiation or continuation of inhaled corticosteroids 32, 33

Adjunctive Therapies

The American College of Chest Physicians suggests considering intravenous magnesium sulfate for severe refractory asthma, with a dose of 2 g IV over 20 minutes for adults and 25-75 mg/kg (maximum 2 g) IV over 20 minutes for children 32, 33

Asthma Exacerbation Management

Initial Assessment and Severity

The British Thoracic Society recommends assessing severity using objective measures, including inability to complete sentences in one breath, respiratory rate >25 breaths/min, peak expiratory flow (PEF) <50% predicted/best, and heart rate >110 beats/min, to identify severe exacerbation features 34
Life-threatening features, such as PEF <33% predicted, silent chest, cyanosis, feeble respiratory effort, bradycardia, hypotension, exhaustion, confusion, or coma, should be recognized promptly 34
Arterial blood gas markers of critical severity, including normal or elevated PaCO₂ (≥42 mmHg) in a breathless patient, severe hypoxia (PaO₂ <8 kPa), or low pH, should be identified 34
Underestimating severity is a critical pitfall, as patients, families, and clinicians frequently fail to recognize dangerous exacerbations due to inadequate objective measurements 34

Critical Pitfalls to Avoid

The British Thoracic Society advises against delaying corticosteroid administration, as they must be given immediately, not after "trying bronchodilators first" 34
Sedatives of any kind should not be administered to patients with acute asthma, according to the British Thoracic Society 34
Bolus aminophylline should not be given to patients already taking oral theophyllines, as recommended by the British Thoracic Society 34

Hospital Admission Criteria

Immediate referral to hospital is required for patients with life-threatening features, such as confusion, drowsiness, silent chest, cyanosis, or PEF <33%, as well as those with features of severe attack persisting after initial treatment, according to the British Thoracic Society 34
A lower threshold for admission is recommended for patients presenting in the afternoon or evening, those with recent nocturnal symptoms, previous severe attacks, or poor social circumstances, as advised by the British Thoracic Society 34

Management of Acute Asthma Exacerbation

Initial Assessment and Severity Classification

Patients with severe exacerbations exhibit features such as dyspnea at rest, respiratory rate >25 breaths/min, heart rate >110 beats/min, inability to complete sentences in one breath, and PEF <40% predicted, according to the Journal of Allergy and Clinical Immunology 35

Reassessment Protocol

Patients with an incomplete response to initial treatment, defined as PEF 40-69% predicted and persistent symptoms, should continue intensive treatment and be admitted to the hospital ward, as recommended by the Journal of Allergy and Clinical Immunology 35
Patients with a poor response to initial treatment, defined as PEF <40% predicted, should be admitted to the hospital and considered for ICU admission if life-threatening features are present, according to the Journal of Allergy and Clinical Immunology 35

Adjunctive Therapies for Severe/Refractory Cases

Intravenous magnesium sulfate is indicated for severe exacerbations with FEV₁ or PEF <40% predicted after initial treatment or life-threatening features, and significantly increases lung function and decreases hospitalization necessity, as reported by the Journal of Allergy and Clinical Immunology 35
Warning signs of impending respiratory failure include drowsiness, confusion, inability to speak, altered mental status, worsening fatigue, silent chest, and PaCO₂ ≥42 mmHg, and patients exhibiting these signs should be considered for immediate ICU transfer, according to the Journal of Allergy and Clinical Immunology 35

Hospital Admission Criteria

The American Thoracic Society and other guideline societies recommend ICU admission for patients with PEF <33% predicted, silent chest, altered mental status, or minimal relief from frequent SABA, as cited in the Journal of Allergy and Clinical Immunology 35

Ongoing Hospital Management

Inhaled corticosteroids should be initiated or continued during hospitalization for patients with acute asthma exacerbation, as recommended by the Journal of Allergy and Clinical Immunology 35

Management of Acute Severe Asthma

Rationale for Treatment

The American Thoracic Society recommends IV magnesium sulfate for patients with severe refractory asthma who fail to respond to initial bronchodilator and corticosteroid therapy 36
Patients with severe asthma exacerbation, characterized by inability to complete sentences, respiratory distress, and bilateral wheezing, may benefit from IV magnesium sulfate 37

Evidence Supporting Magnesium Sulfate

A Cochrane meta-analysis demonstrated that IV magnesium sulfate improves pulmonary function and reduces hospital admissions in patients with severe asthma exacerbations 36
The standard adult dose of IV magnesium sulfate is 2 g administered over 20 minutes, which causes relaxation of bronchial smooth muscle with minor side effects 36

Treatment Algorithm

The American College of Chest Physicians recommends immediately administering IV magnesium sulfate 2 g over 20 minutes for patients with severe asthma who have failed initial treatment 36
Continuing oxygen to maintain SaO2 >90%, nebulized salbutamol, and ipratropium is also recommended 36, 37, 38

Critical Pitfalls to Avoid

Underestimating severity is a common pitfall, and patients, families, and clinicians frequently fail to recognize dangerous exacerbations due to inadequate objective measurements 37
The British Thoracic Society advises against delaying magnesium sulfate while continuing repeated doses of bronchodilators alone 37

Hospital Admission Criteria

The American Thoracic Society recommends hospital admission for patients with persistent features of severe asthma after initial treatment, and considers ICU transfer if there is deteriorating PEF, worsening hypoxia, or other severe symptoms 37, 39, 38

Treatment of Acute Asthma Exacerbation

Initial Treatment and Assessment

The American Thoracic Society recommends IV hydrocortisone 200 mg if unable to take oral corticosteroids in acute asthma exacerbation, with a preference for oral route when possible 40

Adjunctive Therapies

The American Heart Association suggests avoiding methylxanthines (theophylline/aminophylline) due to erratic pharmacokinetics, significant side effects, and lack of evidence of benefit over standard therapy 41

Hospital Admission and Discharge Criteria

The British Thoracic Society recommends immediate admission for patients with peak expiratory flow (PEF) <33% predicted after treatment, and a lower threshold for admission if presentation occurs in the afternoon or evening, recent nocturnal symptoms, or previous severe attacks 40
The British Thoracic Society also recommends ensuring inhaler technique is verified, and follow-up is arranged within 1 week at discharge 40

Asthma Exacerbation Severity and Treatment

Patient Monitoring and Assessment

Tachycardia >110 beats/min in adults or >140 beats/min in children indicates severe exacerbation, though beta-agonist therapy will further increase heart rate 42, 43
In life-threatening asthma, bradycardia or hypotension are ominous signs indicating impending respiratory arrest, not medication effects 42, 43

Management of Refractory Severe Asthma Exacerbation

Immediate Next Steps

The British Thoracic Society recommends continuing nebulized beta-agonists every 15 minutes if there is no improvement after the initial three doses 44
Continue ipratropium bromide 0.5mg via nebulizer every 20 minutes for additional doses, then every 4-6 hours, as the combination with beta-agonists has been proven to reduce hospitalizations 45, 44

Critical Assessment and Monitoring

Immediately prepare for ICU transfer if the patient exhibits life-threatening features such as silent chest, cyanosis, or feeble respiratory effort, altered mental status, bradycardia or hypotension, PaCO₂ ≥42 mmHg or rising, or PEF <33% of predicted or best value 44
Measure PEF or FEV₁ every 15-30 minutes after treatments to guide escalation decisions 44

Additional Interventions to Consider

Obtain a chest X-ray to exclude pneumothorax, consolidation, or pulmonary edema, complications that would change management and explain treatment failure 44
Ensure adequate systemic corticosteroid dosing is maintained - prednisolone 30-60mg orally or IV hydrocortisone 200mg every 6 hours 44
Continue high-flow oxygen 40-60% via mask to maintain SaO₂ >90% 44

Critical Pitfalls to Avoid

Never administer sedatives of any kind to patients with acute asthma exacerbation 44
Consider other treatments before resorting to intubation, but do not delay once respiratory failure is imminent, and transfer to ICU should be accompanied by a physician prepared to intubate 44

Management of Mild Asthma Exacerbation

Initial Treatment and Maintenance

The American College of Allergy, Asthma, and Immunology recommends that patients already using Inhaled Corticosteroid (ICS) maintenance therapy should continue or initiate ICS maintenance therapy upon discharge, as part of their asthma management plan 46
For patients with mild asthma exacerbation, the guideline suggests considering as-needed ICS-SABA combination as an alternative approach, which provides noninferior exacerbation control compared to daily ICS while reducing total ICS exposure 46
The same guideline also notes that quadrupling ICS dose at the first sign of deterioration in patients with poor adherence may result in a nearly 20% reduction in exacerbations, although this strategy may not be effective in adherent patients 46

Special Considerations

The American College of Allergy, Asthma, and Immunology suggests that patients already on ICS should not routinely double or quadruple their ICS dose during an exacerbation if they are adherent to their maintenance therapy, as controlled trials show this strategy may not be effective in adherent patients 46

Acute Asthma Exacerbation Management

Recognition and Assessment

The British Thoracic Society recommends recognizing severe exacerbation features, including inability to complete sentences in one breath, respiratory rate >25 breaths/min, and peak expiratory flow (PEF) <50% of predicted or personal best, in patients with acute asthma 47
Life-threatening features requiring immediate ICU consideration include silent chest, cyanosis, or feeble respiratory effort, bradycardia or hypotension, and normal or elevated PaCO₂ (≥42 mmHg) in a breathless patient, according to the British Thoracic Society 47

Treatment

The British Thoracic Society recommends administering high-dose inhaled beta-agonist, such as salbutamol 5 mg or terbutaline 10 mg, via oxygen-driven nebulizer or 4-8 puffs via metered-dose inhaler (MDI) with spacer every 20 minutes for 3 doses, in patients with acute asthma 47
The British Thoracic Society recommends giving systemic corticosteroids, such as prednisolone 30-60 mg orally or IV hydrocortisone 200 mg, immediately in patients with acute asthma, as clinical benefits require 6-12 hours minimum 47
The British Thoracic Society recommends adding ipratropium bromide 0.5 mg to nebulized beta-agonist every 20 minutes for 3 doses, then as needed, in patients with severe airflow obstruction 47
The British Thoracic Society recommends giving IV aminophylline 250 mg over 20 minutes or salbutamol/terbutaline 250 µg over 10 minutes in patients with severe refractory asthma or PEF <40% after initial treatment 47

Critical Pitfalls to Avoid

The British Thoracic Society recommends never administering sedatives of any kind to patients with acute asthma, as this is absolutely contraindicated 47
The British Thoracic Society recommends not underestimating severity and always measuring PEF or FEV₁ in patients with acute asthma 47

Hospital Admission Criteria

The British Thoracic Society recommends immediate hospital referral for patients with life-threatening features, features of severe attack persisting after initial treatment, according to the British Thoracic Society 47

Management of Asthma Exacerbation

Initial Assessment and Severity Classification

The American Academy of Allergy, Asthma, and Immunology recommends assessing severity immediately using objective measures, not subjective clinical impression alone, as underestimation is a critical and common pitfall, and identifies risk factors requiring heightened vigilance, including previous intubation or ICU admission for asthma, ≥2 hospitalizations or ≥3 ED visits in past year, and recent hospitalization or ED visit within past month 48
Severity categories based on symptoms and peak expiratory flow (PEF) or FEV₁ include life-threatening features such as PEF <33% predicted, silent chest, cyanosis, altered mental status, feeble respiratory effort, bradycardia, hypotension, PaCO₂ ≥42 mmHg 48

Hospital Admission Criteria

The American Academy of Allergy, Asthma, and Immunology recommends immediate hospital admission for any life-threatening features present, features of severe attack persisting after initial treatment, and PEF <50% predicted after 1-2 hours of intensive treatment, and a lower threshold for admission if previous severe attacks or intubation, or poor social circumstances or difficulty perceiving symptom severity 48

Acute Asthma Exacerbation Management

Initial Assessment and Severity Recognition

The British Thoracic Society recommends assessing severity objectively within the first 15-30 minutes using peak expiratory flow (PEF) or FEV₁, as underestimation is the most common preventable cause of asthma deaths 49
Severe exacerbation features include inability to complete sentences in one breath, respiratory rate >25 breaths/min, heart rate >110 beats/min, and PEF <50% of predicted or personal best 49, 50

Immediate Treatment Protocol

The British Thoracic Society recommends giving albuterol 2.5-5 mg via oxygen-driven nebulizer OR 4-8 puffs via MDI with spacer every 20 minutes for 3 doses, with half doses (salbutamol 2.5 mg or terbutaline 5 mg) for children weighing <15 kg 50, 51
For adults, prednisolone 30-60 mg orally OR IV hydrocortisone 200 mg should be given immediately, while for children, prednisolone 1-2 mg/kg (maximum 40 mg) should be administered 49, 50, 51

Escalation for Severe/Refractory Cases

The British Thoracic Society recommends continuing aggressive bronchodilator therapy, with an increase in frequency to every 15 minutes if needed, and considering continuous albuterol nebulization for severe cases 51
IV aminophylline 250 mg over 20 minutes can be considered for adults, but should not be given as a bolus to patients already taking oral theophyllines 49

Critical Pitfalls to Avoid

The British Thoracic Society advises against administering sedatives to patients with acute asthma, as this is absolutely contraindicated 49
Delaying corticosteroid administration while "trying bronchodilators first" is also contraindicated, as steroids must be given immediately 49

Special Populations

For children, half doses of bronchodilators should be used, and prednisolone 1-2 mg/kg (maximum 40 mg) should be repeated for up to 5 days 50, 51
Aminophylline should no longer be used in children at home, according to the British Thoracic Society 50, 51

Acute Asthma Exacerbation Management

Initial Treatment

The American Academy of Allergy, Asthma, and Immunology recommends administering systemic corticosteroids immediately and early, without delaying while trying bronchodilators first, as clinical benefits require a minimum of 6-12 hours to manifest 52
Oral administration of corticosteroids is as effective as intravenous and is preferred unless the patient cannot tolerate oral intake, according to the American Academy of Allergy, Asthma, and Immunology 52
The American Academy of Allergy, Asthma, and Immunology advises against delaying corticosteroid administration while trying bronchodilators first, and recommends giving prednisone 40-60 mg orally in single or divided doses for adults 52
Intravenous magnesium sulfate 2 g over 20 minutes may be effective for life-threatening features or severe exacerbations not responding after 1 hour of intensive treatment, as recommended by the American Academy of Allergy, Asthma, and Immunology 52
The American Academy of Allergy, Asthma, and Immunology warns against administering sedatives to patients with acute asthma exacerbation, as this is absolutely contraindicated 52
Avoiding intravenous isoproterenol due to danger of myocardial toxicity is recommended by the American Academy of Allergy, Asthma, and Immunology 52
The American Academy of Allergy, Asthma, and Immunology recommends not underestimating severity and always measuring PEF or FEV₁ objectively, as subjective assessments are frequently inaccurate 52
No taper is needed for oral corticosteroid courses less than 10 days, especially if the patient is concurrently taking inhaled corticosteroids, according to the American Academy of Allergy, Asthma, and Immunology 52
Patients can be discharged when PEF is greater than or equal to 70% of predicted or personal best, symptoms are minimal or absent, and the patient is stable for 30-60 minutes after the last bronchodilator dose, as recommended by the American Academy of Allergy, Asthma, and Immunology 52

Acute Asthma Exacerbation Management

Initial Assessment and Severity Recognition

The American Thoracic Society recommends that a life-threatening feature of asthma exacerbation is a PEF <33% predicted, which is an ominous sign indicating impending respiratory failure 53

Immediate Treatment Protocol (First Hour)

The British Thoracic Society suggests that for children weighing <15 kg, half doses of bronchodilators (2.5 mg) should be used, and prednisone 1-2 mg/kg (maximum 40-60 mg) should be administered orally 54

Hospital Admission Criteria

The American College of Chest Physicians recommends that immediate hospital admission is required for patients with life-threatening features present, including a PEF <50% predicted after 1-2 hours of intensive treatment, and those with previous severe attacks requiring intubation or ICU admission 53

Special Considerations for Children

The Pediatric Asthma Guidelines recommend that for children, half doses of bronchodilators (salbutamol 2.5 mg) should be used for those weighing <15 kg, and prednisolone dosing is 1-2 mg/kg (maximum 40-60 mg), repeated for up to 5 days if needed 54

Adjunctive Therapies for Moderate-to-Severe Exacerbations

The National Asthma Education and Prevention Program recommends that intravenous magnesium sulfate 2 g over 20 minutes should be administered for life-threatening features present, including a PEF <40% predicted 53

Management of Refractory Cases

The American Thoracic Society recommends that warning signs of impending respiratory failure requiring immediate ICU transfer include drowsiness, confusion, or altered mental status, and a PaCO₂ ≥42 mmHg or rising 53

Critical Pitfalls to Avoid

The British Thoracic Society suggests that bolus aminophylline should not be given to patients already taking oral theophyllines, as methylxanthines have increased side effects without superior efficacy 54, 53

Evidence‑Based Asthma Peak Flow Zone Management

Yellow Zone (50–79 % of Personal Best) – Caution Zone

Patients entering the yellow zone should receive immediate escalation of therapy with systemic oral corticosteroids and increased short‑acting β‑agonist (SABA) use to prevent progression to severe exacerbation. 55
Peak flow should be measured before and after each bronchodilator dose to assess response and guide further action. 56

Red Zone (<50 % of Personal Best) – Medical Alert

Emergency treatment is required: high‑dose inhaled bronchodilators (e.g., albuterol 5 mg nebulized or 4–8 puffs MDI every 20 min for three doses), systemic corticosteroids (prednisolone 40–60 mg PO or IV hydrocortisone 200 mg), optional ipratropium bromide, and supplemental oxygen to keep SaO₂ > 90 %; patients must proceed directly to the emergency department or call emergency services. 56
Life‑threatening features that warrant ICU consideration include peak flow < 33 % of predicted or personal best, silent chest, cyanosis, feeble respiratory effort, altered mental status, bradycardia or hypotension, and a normal or elevated PaCO₂ (≥ 42 mmHg) in a breathless patient. 56

Pediatric Considerations

Children older than 5 years can reliably use peak flow meters for monitoring. 57
In children, a peak flow variability > 13 % is indicative of asthma, whereas the adult threshold is > 10 %. [58][59]
Arterial blood gas analysis is rarely useful in deciding the initial management of acute asthma in children. 56

Discharge and Follow‑Up Criteria

Patients should not be discharged until peak flow reaches ≥ 75 % of predicted or personal best, diurnal variability is < 25 %, and they remain clinically stable for 30–60 minutes after the last bronchodilator dose. 56
At discharge, clinicians must ensure the patient has been on the prescribed discharge medications for 24 hours, verify correct inhaler technique, provide a written self‑management plan with zone‑based instructions, and prescribe a peak flow meter if one is not already available. [56][55]
Arrange general‑practice follow‑up within 1 week and a respiratory‑clinic appointment within 4 weeks to reassess control and reinforce the action plan. [56][55]

Acute Asthma Exacerbation Management Guidelines

Immediate First‑Line Treatment (First 15–30 min)

Administer high‑dose inhaled short‑acting β₂‑agonist (albuterol 5 mg or terbutaline 10 mg via oxygen‑driven nebuliser, or 4–8 puffs via MDI with spacer every 20 min for three doses) together with systemic corticosteroids (prednisolone 40–60 mg orally in adults, or IV hydrocortisone 200 mg) and supplemental oxygen to keep SaO₂ > 90% (target > 95% in pregnancy or cardiac disease) 60, 61
In children, give prednisolone 1–2 mg/kg (maximum 40–60 mg) orally; for those weighing < 15 kg use half the adult dose (≈2.5 mg albuterol) 61
Record peak expiratory flow (PEF) or FEV₁ before treatment and again 15–30 min after the first bronchodilator dose to guide escalation 60

Severity Assessment & Risk Stratification

Severe exacerbation indicators – inability to speak a full sentence in one breath, respiratory rate > 25 breaths/min (adults) or > 50 breaths/min (children), heart rate > 110 bpm (adults) or > 140 bpm (children), and PEF < 50 % of predicted or personal best 60, 61
Life‑threatening indicators – PEF < 33 % of predicted, silent chest, cyanosis or markedly feeble respiratory effort, altered mental status (confusion, drowsiness, exhaustion), and bradycardia or hypotension 60, 61

Escalation Protocol (If No Improvement After First Three Doses)

Add ipratropium bromide 0.5 mg to the nebuliser (or 8 puffs via MDI) every 20 min for three doses, then every 4–6 h until clinical response 60, 61
Increase β₂‑agonist frequency to every 15–30 min or switch to continuous nebulisation for markedly severe cases 60
Continue oxygen to maintain SaO₂ > 90% and maintain systemic corticosteroid therapy 60, 61
Give IV hydrocortisone 200 mg every 6 h in patients who are vomiting or critically ill (a single 100 mg dose is insufficient) 60
For refractory severe asthma, administer IV aminophylline 250 mg over 20 min (or IV salbutamol/terbutaline 250 µg over 10 min); do not give a bolus aminophylline to patients already on oral theophylline 60
In children, aminophylline dosing is 5 mg/kg over 20 min followed by a maintenance infusion of 1 mg/kg/h 60, 61

Monitoring Throughout Treatment

Measure PEF or FEV₁ before and after each bronchodilator dose and at least every 4 h thereafter 60
Provide continuous pulse‑oximetry, aiming for SaO₂ > 92% 61
Obtain arterial blood gases when life‑threatening features appear or when PaCO₂ concerns arise 60
Perform chest radiography to rule out pneumothorax, pneumomediastinum, consolidation, or pulmonary oedema in patients not responding to therapy 60

Hospital Admission & ICU Transfer Criteria

Immediate admission for any life‑threatening feature (PEF < 33 %, silent chest, altered mental status, respiratory acidosis) 60, 61
Admit if severe attack features persist after initial intensive treatment 61
ICU transfer indicated by deteriorating PEF despite therapy, worsening or persistent hypoxia/hypercapnia, exhaustion or altered consciousness, and impending respiratory arrest 61

Discharge Planning

Verify inhaler technique and document competency 60, 61
Provide a written self‑management plan with peak‑flow zones 60
Supply a peak‑flow meter if the patient does not already have one 60, 61
Arrange follow‑up with the primary‑care physician within 1 week and with a respiratory clinic within 4 weeks 60, 61

Critical Pitfalls to Avoid

Never administer sedative agents to patients with acute asthma, as they are absolutely contraindicated 60

All facts are derived from cited sources 60 and 61; strength of evidence was not explicitly stated in the source material.

Management of Acute Asthma Exacerbations – Evidence‑Based Recommendations

Severity Assessment

Severe exacerbation indicators – inability to speak a full sentence in one breath, respiratory rate > 25 breaths/min, heart rate > 110 beats/min, and peak expiratory flow (PEF) < 50 % of predicted or personal best are associated with a higher risk of treatment failure. 62
Life‑threatening signs – PEF < 33 % of predicted, silent chest, cyanosis, weak respiratory effort, bradycardia or hypotension, altered mental status (confusion, somnolence), and a normal or elevated arterial CO₂ ≥ 42 mm Hg in a dyspneic patient signal imminent respiratory collapse and mandate intensive‑care evaluation. 62
Preventable mortality – Under‑recognizing severity is the most common preventable cause of asthma death; objective measurement of PEF or FEV₁ is essential rather than relying solely on subjective clinical impression. 62

Initial Treatment Response (15–30 min after first bronchodilator)

Good response (PEF > 75 % predicted) – Continue the patient’s usual maintenance regimen (with a modest increase if needed), monitor trends with a PEF chart, and arrange a follow‑up visit within 48 hours. 62
Incomplete response (PEF 50–75 % predicted) – Maintain nebulized albuterol every 4–6 hours, continue systemic corticosteroids, and consider hospital admission if severe features persist. 62
Poor response (PEF < 50 % predicted or persistent severe features) – Increase albuterol nebulizations to every 15–30 minutes, add ipratropium bromide, and arrange immediate hospital admission. 62

Adjunctive Pharmacologic Therapies

Aminophylline – A single intravenous dose of 250 mg over 20 minutes may be used for refractory severe asthma with life‑threatening features. 62
Safety caution for aminophylline – Do not give an aminophylline bolus to patients already receiving oral theophylline, because of heightened toxicity without added benefit. 62

Hospital Admission Criteria

Admit immediately when any life‑threatening sign is present, when severe‑attack features remain after initial therapy, when PEF remains < 33 % of predicted after treatment, or when PEF is < 50 % after 1–2 hours of intensive therapy. 62
Lower threshold for admission – Evening or night presentation, recent nocturnal symptoms, prior severe attacks requiring intubation or ICU care, ≥ 2 hospitalizations or ≥ 3 emergency‑department visits in the past year, or inadequate social support that limits reliable monitoring. 62

Discharge Planning

Readiness for discharge – PEF ≥ 70–75 % of predicted, minimal or absent symptoms, stable oxygen saturation on room air, and clinical stability for 30–60 minutes after the last bronchodilator dose. 62
Post‑discharge medication – Continue oral corticosteroids for 5–10 days (no taper needed for courses < 10 days) and initiate or maintain inhaled corticosteroids. 62
Education and follow‑up – Verify correct inhaler technique, provide a written asthma action plan with zone‑based instructions, supply a peak‑flow meter if the patient does not already have one, arrange primary‑care follow‑up within 1 week and specialty follow‑up within 4 weeks. 62

Critical Safety Considerations

Sedatives are contraindicated in acute asthma exacerbations; their use is absolutely prohibited. 62
Avoid reliance on subjective assessment – Objective PEF/FEV₁ measurements must guide severity evaluation to prevent missed life‑threatening deterioration. 62
Do not give aminophylline bolus to patients already on oral theophylline (see above). 62
Inhaler‑technique verification is required before discharge to ensure effective self‑administration of rescue and controller medications. 62

Acute Asthma Exacerbation Management in Urgent‑Care Settings

Immediate Treatment

Administer high‑dose inhaled short‑acting β₂‑agonist immediately (e.g., albuterol 2.5–5 mg via nebulizer or 4–8 puffs via metered‑dose inhaler with spacer, repeated every 20 minutes for three doses) to rapidly reverse airflow obstruction. – National Asthma Education and Prevention Program (NAEPP) 63
Give systemic corticosteroid without delay – oral prednisone 40–60 mg as a single dose (or divided twice) for adults; anti‑inflammatory effect begins within 6–12 hours. – NAEPP 63
Measure peak expiratory flow (PEF) or FEV₁ before and 15–30 minutes after the first bronchodilator dose to objectively gauge severity and response. – NAEPP 63
Provide supplemental oxygen when SpO₂ < 90 % (target > 95 % in pregnant patients or those with cardiac disease). – NAEPP 63

Severity Assessment & Disposition

Severe exacerbation criteria (indicating need for hospital transfer): inability to speak a full sentence in one breath, respiratory rate > 25 breaths/min, heart rate > 110 beats/min, and PEF < 50 % of predicted or personal best. – NAEPP 63
Life‑threatening features (mandating immediate emergency‑department transfer): PEF < 33 % predicted, silent chest, cyanosis, altered mental status, or normal/elevated PaCO₂ ≥ 42 mmHg in a dyspneic patient. – NAEPP 63

Discharge Planning (when safe)

Discharge eligibility: PEF > 70 % predicted after initial therapy, minimal symptoms, and clinical stability for 30–60 minutes after the last bronchodilator dose. – NAEPP 63
Prescribe oral prednisone 40–60 mg daily for 5–10 days (no taper required for courses < 10 days). – NAEPP 63
Provide an albuterol rescue inhaler at discharge (dispensed from urgent‑care stock, same‑day pharmacy delivery, or 24‑hour pharmacy referral). – NAEPP 63

Corticosteroid Route & Dosing

Oral prednisone is as effective as intravenous methylprednisolone or hydrocortisone when gastrointestinal absorption is intact; oral route is preferred because it is less invasive. – NAEPP 63
Reserve intravenous corticosteroids for patients who are actively vomiting, severely ill and unable to tolerate oral intake, or have impaired GI absorption. – NAEPP 63
Adult dosing: prednisone 40–60 mg once daily (or divided twice daily) for 5–10 days, no taper. – NAEPP 63
Pediatric dosing: prednisone or prednisolone 1–2 mg/kg/day (maximum 60 mg/day) in two divided doses for 3–10 days, no taper. – NAEPP 63
Equivalent alternatives: prednisolone 40–60 mg/day or methylprednisolone 40–80 mg/day on the same schedule. – NAEPP 63

Clinical Pitfalls to Avoid

Do not delay corticosteroid administration while “trying bronchodilators first”; both should be given concurrently. – NAEPP 63
Never discharge a patient without immediate access to a rescue bronchodilator; waiting until the next day is unacceptable. – NAEPP 63
Do not rely solely on subjective clinical impression; objective PEF or FEV₁ measurement is essential to prevent underestimation of severity. – NAEPP 63
Avoid sedative medications in patients with acute asthma, as they are contraindicated. – NAEPP 63

Evidence Basis

These recommendations are grounded in high‑quality evidence from the National Asthma Education and Prevention Program Expert Panel Report 3 and the British Thoracic Society guidelines, as well as multiple international consensus statements (BMJ 1996 64; Mayo Clinic Proceedings 2009 65). – NAEPP, BTS 63

Emergency Referral and Management of Acute Asthma Exacerbations

Immediate Emergency Department Referral – Life‑Threatening Features

A patient with a peak expiratory flow (PEF) < 33 % of predicted or personal best should be transferred immediately to the emergency department. [66][67]
Presence of a silent chest, cyanosis, or markedly reduced respiratory effort mandates urgent ED transfer. [66][67]
Altered mental status (confusion, drowsiness, exhaustion, or coma) is a red‑flag requiring immediate ED referral. [66][67]
Bradycardia or hypotension in the setting of an acute asthma attack signals life‑threatening compromise and requires ED transfer. [66][67]
A normal or elevated arterial CO₂ ≥ 42 mm Hg in a breathless patient indicates impending respiratory failure and warrants immediate ED referral. 66
Severe hypoxaemia (PaO₂ < 8 kPa ≈ 60 mm Hg) despite supplemental oxygen is an indication for urgent ED transfer. 66
A history of prior intubation or intensive‑care admission for asthma lowers the threshold for immediate ED referral. [66][67]

Severe Exacerbation Features Requiring ED Referral After Initial Out‑patient Treatment

Inability to speak full sentences in a single breath after initial therapy signals the need for hospital referral. [66][67]
Respiratory rate > 25 breaths/min persisting after initial treatment warrants ED referral. [66][67]
Heart rate > 110 beats/min after initial therapy is a criterion for emergency department referral. [66][67]
PEF < 50 % of predicted or personal best after initial treatment requires hospital referral. [66][67]
If PEF measured 15–30 minutes after the first nebulised bronchodilator remains < 33 % of predicted, immediate ED referral is indicated. [66][67]

Lower Threshold for Hospital Admission

Presentations occurring in the afternoon or evening (rather than morning) should prompt a lower threshold for admission. [66][67]
Recent nocturnal symptoms or a worsening pattern of symptoms increase the likelihood of admission. [66][67]
A history of previous severe attacks, especially with rapid onset, lowers the admission threshold. [66][67]
Clinician concern about the patient’s ability to self‑assess severity justifies earlier admission. [66][67]
Poor social circumstances or inadequate support systems are additional reasons to admit promptly. [66][67]

Out‑patient Management Eligibility Criteria

Patients may be managed at home only if, after initial treatment, they can speak full sentences, have a respiratory rate < 25 /min, heart rate < 110 /min, and PEF > 50 % of predicted. [66][67]

Immediate Out‑patient Treatment Protocol

High‑dose inhaled β₂‑agonist: Salbutamol 5 mg (or terbutaline 10 mg) via oxygen‑driven nebuliser, or 4–8 puffs of a metered‑dose inhaler with spacer every 20 minutes for three doses. [66][67]
Systemic corticosteroid: Prednisolone 30–60 mg orally administered immediately (do not delay while “trying bronchodilators first”). [66][67]
PEF reassessment: Measure PEF 15–30 minutes after the first bronchodilator dose to guide further management. [66][67]

Response‑Based Out‑patient Management

Good response (PEF > 75 % predicted): Continue usual maintenance therapy, monitor symptoms and PEF on a chart, and arrange follow‑up within 48 hours. 67
Incomplete response (PEF 50–75 % predicted): Administer an additional oral prednisolone 30–60 mg, step up usual treatment, and schedule review within 48 hours. 67
Poor response (PEF < 50 % predicted or persistent severe features):
- Arrange immediate hospital admission. [66][67]
- Repeat nebulised β₂‑agonist. 67
- Add ipratropium bromide 0.5 mg to the nebuliser. [66][67]

Critical Safety Pitfall

Objective PEF measurement is mandatory in acute asthma; failure to obtain an objective PEF is the most common preventable cause of asthma‑related death. 66

Specialist Follow‑up and Referral Criteria

Primary‑care follow‑up should occur within 1 week of any acute exacerbation. 66
Respiratory‑specialist clinic review should be scheduled within 4 weeks. 66
Indications for referral to a respiratory specialist include:
- Any patient who required hospital admission for the exacerbation. [66][67]
- Moderate exacerbations that necessitated systemic corticosteroids. 67
- A previous life‑threatening attack or intensive‑care admission. 66

Discharge Requirements Before Leaving the ED/Clinic

Verify correct inhaler technique with the patient. 66
Provide a written self‑management plan that includes defined PEF zones. 66

Absolute Contraindications in Acute Asthma

Administration of any sedative medication is absolutely contraindicated and may be fatal. [66][67]

Nebulizer Equivalent Dosing for Salbutamol in Acute Asthma Exacerbation

Dose Equivalence

In patients experiencing mild‑to‑moderate acute asthma exacerbations, administering nebulized salbutamol 2.5–5 mg every 20 minutes for three consecutive doses provides bronchodilation comparable to delivering 4–8 puffs (360–720 µg) of salbutamol via metered‑dose inhaler with a spacer. 68, 69

Acute Management of Severe Asthma Exacerbation

Immediate Dual Bronchodilator Therapy

Administer a nebulized combination of ipratropium (0.5 mg) and albuterol (2.5–5 mg) every 20 minutes for three doses during the first hour, then continue every 4–6 hours as needed for moderate‑to‑severe exacerbations. 70
If the response after the first hour is inadequate, increase nebulizer frequency to every 15–30 minutes and arrange urgent emergency‑department transfer. 71
Adding ipratropium to albuterol reduces the risk of hospitalization, especially in patients with severe airflow obstruction. 70

Systemic Corticosteroid Intervention

Give oral prednisone 40–60 mg immediately (single dose today) and continue daily for a total of 5–10 days; no taper is required for this short course. 70
Oral administration is as effective as intravenous delivery and is strongly preferred. 70
Early corticosteroid use (within the first hours of exacerbation) is essential to prevent progression to respiratory failure; delayed therapy is a leading preventable cause of asthma mortality. 71

Imaging Recommendation

Obtain a chest radiograph to rule out pneumonia, pneumothorax, or pulmonary edema in individuals with severe exacerbation features (e.g., near‑syncope, nocturnal awakening, or atypical sputum). 71

Initiation of Controller Therapy During Exacerbation

Start a high‑dose inhaled corticosteroid/long‑acting β₂‑agonist (ICS/LABA) immediately—e.g., fluticasone 250 µg/salmeterol 50 µg, one inhalation twice daily. This step‑up therapy is appropriate for persistent moderate‑to‑severe asthma and can be initiated during an acute episode. 70

Monitoring and Reassessment Protocol

Measure peak expiratory flow (PEF) before treatment and again 15–30 minutes after the first nebulizer dose. [70][71]
Response‑based actions:
- Good response (PEF > 75 % predicted): Continue home management with close follow‑up. 71
- Partial response (PEF 50–75 % predicted): Maintain intensive bronchodilator dosing every 4 hours, continue oral steroids, and arrange reassessment within 24–48 hours. 71
- Poor response (PEF < 50 % predicted or persistent severe symptoms): Immediate emergency‑department referral. 71
Red‑flag criteria prompting ED transfer: inability to speak full sentences, respiratory rate > 25/min, heart rate > 110/min, PEF < 50 % after initial therapy, altered mental status, silent chest, or cyanosis. 71

Inhaler Technique and Education

Verify proper technique for metered‑dose inhalers or nebulizers before discharge; provide a spacer device when using an MDI. 71

Follow‑Up and Specialist Referral

Schedule a primary‑care follow‑up within 1 week and a pulmonology referral within 4 weeks. 71
Supply a written asthma action plan that includes PEF zones and clear instructions for step‑up therapy or urgent care. 71

Safety Considerations for Discharge

Do not use sedative medications in acute asthma; they are absolutely contraindicated. 71
Objective PEF measurement is mandatory for discharge decisions; subjective assessment alone is insufficient. 71
Ensure the patient remains stable for at least 24 hours on prescribed medications, has verified inhaler technique, and possesses a written action plan before discharge. 71

Evidence‑Based Management of Acute Asthma Exacerbation in Adults

Oxygen Therapy

Target peripheral oxygen saturation ≥ 92 % in non‑pregnant adults using a nasal cannula or face mask. [72][73]

Bronchodilator Dosing for Poor Response

If peak expiratory flow remains < 50 % predicted or severe features persist after initial therapy, increase albuterol administration to every 15–30 minutes. 72

Inhaled Anticholinergic Adjunct

Add ipratropium bromide to albuterol for all moderate‑to‑severe exacerbations; give 0.5 mg nebulized every 20 minutes for three doses, then every 4–6 hours as needed. 72

Contra‑indicated Therapies

Sedatives must never be administered to patients with acute asthma exacerbation because they can be fatal. 72
A bolus of intravenous aminophylline should be avoided in patients already receiving oral theophylline. 72

ICU Transfer Criteria (Persistent Deterioration)

Transfer to intensive care when any of the following occur despite therapy:

Discharge Planning – Patient Education & Equipment

Verify correct inhaler technique and document competency before discharge. [72][73]
Provide a written self‑management plan that includes individualized peak‑flow zones. [72][73]
Supply a peak‑flow meter to any patient who does not already possess one. [72][73]

Follow‑Up After Discharge

Arrange primary‑care follow‑up within 1 week of discharge. [72][73]
Arrange follow‑up in a respiratory‑specialist clinic within 4 weeks of discharge. [72][73]